- ***Why carry out this study?***
- Overall survival as the primary endpoint of the DAC-016 study was not met and decitabine was not approved by the FDA in acute myeloid leukemia (AML).
- Though pre-specified, the log-rank test could be considered not optimal to assess the observed survival difference because of the non-proportional hazard nature of the survival curves.
- Wilcoxon test is considered more powerful as it assigns more weight to earlier events. Wilcoxon test indicated significant increase in survival for decitabine versus treatment choice.
- ***What was learned from the study?***
- It should be possible to ex-ante include different test options in a statistical analysis plan making their respective use dependent on the proportionality of hazard rates.
- In the future an adaptively-weighted log-rank test might be appropriate because it maintains optimality at the proportional alternatives, while improving the power over a wide range of non-proportional alternatives.

This summary slide represents the opinions of the authors. Sponsorship, article processing charges, and the open access charge for this study were funded by Janssen-Cilag GmbH, Germany. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online.